|
業務類別
|
Biotechnology |
|
業務概覽
|
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals. |
| 公司地址
| 275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065 |
| 電話號碼
| +1 650 206-4507 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.rezolutebio.com |
| 員工數量
| 71 |
| Mr. Daron Evans |
Chief Financial Officer |
美元 421.46K |
07/10/2025 |
| Mr. Nevan Charles Elam, J.D. |
Acting Chairman of the Board, Chief Executive Officer and Principal Financial Officer |
美元 610.83K |
07/10/2025 |
| Dr. Brian Kenneth Roberts, M.D. |
Chief Medical Officer |
美元 483.36K |
07/10/2025 |
| Mr. Sunil Karnawat |
Chief Commercial Officer |
-- |
20/08/2025 |
|
|
| Mr. Gil M. Labrucherie |
Independent Director |
07/10/2025 |
| Mr. Nevan Charles Elam, J.D. |
Acting Chairman of the Board, Chief Executive Officer and Principal Financial Officer |
07/10/2025 |
| Mr. Philippe Fauchet |
Independent Director |
07/10/2025 |
| Dr. Nerissa C. Kreher, M.D. |
Independent Director |
07/10/2025 |
| Dr. Wladimir Hogenhuis, M.D. |
Independent Director |
07/10/2025 |
| Mr. Erik Harris |
Independent Director |
07/10/2025 |
| Mr. Young-jin Kim |
Director |
07/10/2025 |
|
|
|
|
